CDMO Digitizes Logbooks for Robotics

- Paper-based logbooks in GMP environments are prone to human error, including incomplete, inaccurate, or illegible entries, which can lead to compliance issues and FDA 483 observations. Digital systems mitigate this by capturing data directly in real-time, which is a requirement for compliance. - The ValGenesis VLMS 5.0 is designed to be a "single source of truth" that standardizes validation protocols across different departments and sites, which helps to enforce compliance and minimize errors. This version introduces AI capabilities and is the only validation lifecycle management solution on the market that is ready for the FDA's Computer Software Assurance (CSA) methodology out of the box. - In the context of viral vector manufacturing, automation is critical for reducing processing time and variability, especially when working with multiple adherent cell culture vessels. Automating processes like single-cell seeding and cell culture can also reduce the risk of contamination. - The global viral vector manufacturing market was valued at $1.74 billion in 2024 and is projected to reach $5.76 billion by 2031, growing at a CAGR of 18.8%. This growth is driven by the expanding pipeline of gene and cell therapies, which rely on a steady supply of high-quality vectors. - Digital twin technology allows for the creation of a virtual replica of a manufacturing process, which can be used to simulate and optimize complex biological operations like cell culture and fermentation. This can reduce process development costs and the number of required Process Performance Qualification (PPQ) runs for validation. - For cell and gene therapies, which often involve living cells and are inherently variable, scaling up from clinical to commercial production presents unique challenges compared to traditional biologics. CDMOs with specialized facilities and expertise play a crucial role for the approximately 90% of biotechs that rely on them for manufacturing and regulatory support. - Electronic records in GMP environments must comply with regulations like the FDA's 21 CFR Part 11, which ensures that electronic records and signatures are as trustworthy and reliable as their paper counterparts. Key requirements include secure, time-stamped audit trails that capture all data changes. - The broader Pharma 4.0 initiative involves integrating technologies like IoT, AI, and robotics to create interconnected and intelligent manufacturing processes. This allows for real-time monitoring and predictive maintenance, where AI can analyze data from sensors to anticipate equipment failure before it occurs.